Physician profile
Bart M Olash
NPI 1366559015
$10,030.08
in general payments reported to CMS, 2019-2025
43 companies · $1,134 in 2025
The $1,134 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $821 · 2020: $1,377 · 2021: $1,973 · 2022: $1,721 · 2023: $1,737 · 2024: $1,267 · 2025: $1,134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,137.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,634.94 | 2019-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $913.46 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $893.42 | 2019-2025 | Leqvio |
| Novo Nordisk INC | $743.71 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $584.99 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $502.99 | 2019-2024 | Cycloset, Trulance, Uceris |
| Pfizer INC. | $441.66 | 2019-2025 | |
| Esperion Therapeutics, INC. | $431.79 | 2020-2025 | Nexletol |
| Glaxosmithkline, LLC. | $431.08 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $407.91 | 2019-2023 | Xarelto |
| Lilly USA, LLC | $360.87 | 2019-2025 | Zepbound, Mounjaro, Emgality |
| Sumitomo Pharma America, INC. | $313.26 | 2023-2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $281.11 | 2019-2025 | Jascayd, Jardiance |
| Amarin Pharma, INC. | $275.88 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $239.46 | 2022-2023 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bart Olash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.